FDA Approves Tirzepatide as First Treatment for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity
FDA officials granted regulatory approval to tirzepatide (Zepbound; Eli Lilly and Company) as the first and only prescription medicine for adult patients with moderate-to-severe obstructive sleep apnea (OSA) and obesity, in combination with a reduced- …